Afro-Caribbean heart failure in the United Kingdom

Circulation: Heart Failure

Volumn 9, Issue 9, 2016, Pages

  Dungu, Jason N ^a,b   Papadopoulou, Sofia A ^a   Wykes, Katharine ^a   Mahmood, Ihtisham ^a   Marshall, Joseph ^a   Valencia, Oswaldo ^a   Fontana, Marianna ^b   Whelan, Carol J ^b   Gillmore, Julian D ^b   Hawkins, Philip N ^b   Anderson, Lisa J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

amyloid; blacks; ethnology; heart failure; prognosis

Indexed keywords

ADULT; AFRICAN CARIBBEAN; AGED; ARTICLE; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART FAILURE; HISTOPATHOLOGY; HUMAN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NONISCHEMIC CARDIOMYOPATHY; OUTCOME ASSESSMENT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; SURVIVAL RATE; UNITED KINGDOM; ADOLESCENT; AMYLOID NEUROPATHIES, FAMILIAL; BLACK PERSON; CARDIOMYOPATHIES; CARIBBEAN; CAUCASIAN; DNA MUTATIONAL ANALYSIS; ENGLAND; EPIDEMIOLOGY; ETHNOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; ONSET AGE; PREDICTIVE VALUE; RISK FACTOR; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

PREALBUMIN;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE OF ONSET; AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; CARIBBEAN REGION; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; LONDON; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PREALBUMIN; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84988661362     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003352     Document Type: Article

References (35)

1. Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ, National Heart Failure Audit Team for England and Wales The national heart failure audit for England and Wales 2008-2009. Heart 2011 97 876 886. doi: 10.1136/hrt.2010.209171
2. Office for National Statistics (ONS) Ethnicity and National Identity in England and Wales 2011. 2012
3. Yancy CW, Heart failure in African Americans. Am J Cardiol 2005 96 7B 3i 12i. doi: 10.1016/j.amjcard.2005.07.028
4. Gill PS, Calvert M, Davis R, Davies MK, Freemantle N, Lip GY, Prevalence of heart failure and atrial fibrillation in minority ethnic subjects: the Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). PLoS One 2011 6 e26710. doi: 10.1371/journal.pone.0026710
5. Chaturvedi N, McKeigue PM, Marmot MG, Resting and ambulatory blood pressure differences in Afro-Caribbeans and Europeans. Hypertension 1993 22 90 96
6. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN, Cardiac transthyretin amyloidosis. Heart 2012 98 1546 1554. doi: 10.1136/heartjnl-2012-301924
7. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN, Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid 2015 22 171 174. doi: 10.3109/13506129.2015.1051219
8. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR, Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 2012 164 222 228.e1. doi: 10.1016/j.ahj.2012.04.015
9. Coelho T, Maurer MS, Suhr OB, THAOS-The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013 29 63 76. doi: 10.1185/03007995.2012.754348
10. Carroll JD, Gaasch WH, McAdam KP, Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982 49 9 13
11. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P, Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation 1987 75 565 572
12. Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS, Bailey JJ, Childers R, Gorgels A, Josephson M, Kors JA, Macfarlane P, Mason JW, Pahlm O, Rautaharju PM, Surawicz B, van Herpen G, Wagner GS, Wellens H, American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009 53 992 1002. doi: 10.1016/j.jacc.2008.12.015
13. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group; American Society of Echocardiography?s Guidelines and Standards Committee; European Association of Echocardiography Recommendations for chamber quantification: a report from the American Society of Echocardiography?s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005 18 1440 1463. doi: 10.1016/j.echo.2005.10.005
14. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N, Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986 57 450 458
15. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ, CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014 7 133 142. doi: 10.1016/j.jcmg.2013.08.015
16. Hundley WG, Bluemke D, Bogaert JG, Friedrich MG, Higgins CB, Lawson MA, McConnell MV, Raman SV, van Rossum AC, Flamm S, Kramer CM, Nagel E, Neubauer S, Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson 2009 11 5. doi: 10.1186/1532-429X-11-5
17. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C, Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005 46 1076 1084. doi: 10.1016/j.jacc.2005.05.073
18. Talmud P, Tybjaerg-Hansen A, Bhatnagar D, Mbewu A, Miller JP, Durrington P, Humphries S, Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis 1991 89 137 141
19. Booth DR, Tan SY, Hawkins PN, Pepys MB, Frustaci A, A novel variant of transthyretin, 59Thr->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation 1995 91 962 967
20. Puchtler H, Sweat F, Levine M, On the binding of Congo red by amyloid. J Histochem Cytochem 1962 10 355
21. Tennent GA, Isolation and characterization of amyloid fibrils from tissue. Methods Enzymol 1999 309 26 47
22. Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, Costello CE, O'Hara C, Seldin DC, Skinner M, Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009 158 607 614. doi: 10.1016/j.ahj.2009.08.006
23. Agyemang C, Humphry RW, Bhopal R, Divergence with age in blood pressure in African-Caribbean and white populations in England: implications for screening for hypertension. Am J Hypertens 2012 25 89 96. doi: 10.1038/ajh.2011.160
24. Agyemang C, Bhopal R, Is the blood pressure of people from African origin adults in the UK higher or lower than that in European origin white people? A review of cross-sectional data. J Hum Hypertens 2003 17 523 534. doi: 10.1038/sj.jhh.1001586
25. Dungu J, Sattianayagam PT, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Hawkins PN, Anderson LJ, The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J 2012 164 72 79. doi: 10.1016/j.ahj.2012.04.013
26. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, Dungu J, Banypersad SM, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD, Systemic amyloidosis in England: an epidemiological study. Br J Haematol 2013 161 525 532. doi: 10.1111/bjh.12286
27. Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD, The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 2015 372 21 29. doi: 10.1056/NEJMoa1404852
28. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P, Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015 36 2585 2594. doi: 10.1093/eurheartj/ehv338
29. Ruberg FL, Berk JL, Transthyretin (TTR) cardiac amyloidosis. Circulation 2012 126 1286 1300. doi: 10.1161/CIRCULATIONAHA.111.078915
30. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN, Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997 336 466 473. doi: 10.1056/NEJM199702133360703
31. Lachmann HJ, A new era in the treatment of amyloidosis? N Engl J Med 2013 369 866 868. doi: 10.1056/NEJMe1308768
32. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB, Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013 369 819 829. doi: 10.1056/NEJMoa1208760
33. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR, Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013 260 2802 2814. doi: 10.1007/s00415-013-7051-7
34. Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB, Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 2015 373 1106 1114. doi: 10.1056/NEJMoa1504942
35. Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, Kyriakides T, European Network for TTR-FAP (ATTReuNET) Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 2016 29 suppl 1 S27 S35. doi: 10.1097/WCO.0000000000000290